Literature DB >> 11958839

Nitric-oxide-synthase-mediated cyclic guanosine monophosphate production in neonatal rat cerebellar prisms is resistant to calcineurin inhibition.

Malcolm R Macleod1, Steven P Butcher.   

Abstract

Although the macrolide immunosuppressant tacrolimus (FK506) is neuroprotective in animal models of focal and global cerebral ischaemia, the mechanism of this action is not known. FK506 inhibits the protein phosphatase calcineurin, whose substrates can include nitric oxide synthase (NOS), and the neuroprotective effect of FK506 has been attributed to inhibition of NOS activity. We have examined nitric oxide-mediated cyclic guanosine monophosphate (cGMP) accumulation in neonatal rat cerebellar prisms. As expected, N-methyl-D-aspartate (NMDA) induced a rapid, concentration dependent accumulation of cGMP that was inhibited by the NMDA receptor antagonist dizocilpine (MK801) and the NOS inhibitor L-nitro-arginine methyl ester. Phosphoserine immunopositivity following NMDA exposure was increased in the presence of FK506, confirming inhibition of calcineurin. However, FK506 had no effect on NMDA-stimulated cGMP accumulation. These findings suggest that the neuroprotective effect of FK506 may be mediated by mechanisms other than increased NOS phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11958839     DOI: 10.1016/s0304-3940(02)00080-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Regulation of the mouse Na+-dependent glutamate/aspartate transporter GLAST: putative role of an AP-1 DNA binding site.

Authors:  Guadalupe Ramírez-Sotelo; Esther López-Bayghen; L Clara R Hernández-Kelly; J Antonio Arias-Montaño; Alfonso Bernabé; Arturo Ortega
Journal:  Neurochem Res       Date:  2006-12-07       Impact factor: 3.996

Review 2.  Neuronal nitric oxide synthase expression in cerebellar mutant mice.

Authors:  Louise C Abbott; Sang-Soep Nahm
Journal:  Cerebellum       Date:  2004       Impact factor: 3.648

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.